Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study

• Jorge R. Georgakopoulos, MD,
• Tina Felfeli, MD,
• Aaron M. Drucker, MD, ScM, FRCPC,
• Christine E. Jo, BSc,
• Vincent Piguet, MD, PhD, FRCP,
• Jensen Yeung, MD, FRCPC

Affiliations

Jorge R. Georgakopoulos, MD

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Tina Felfeli, MD

Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

Aaron M. Drucker, MD, ScM, FRCPC

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Women's College Hospital, Toronto, Ontario, Canada

Christine E. Jo, BSc

Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Vincent Piguet, MD, PhD, FRCP

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Women's College Hospital, Toronto, Ontario, Canada

Jensen Yeung, MD, FRCPC

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Women's College Hospital, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Probity Medical Research Inc, Waterloo, Ontario, Canada; Correspondence to: Jensen Yeung, MD, FRCPC, Department of Dermatology, Women's College Hospital, 76 Grenville St, Fifth Floor, Toronto, Ontario M5S 1B2, Canada